Daxor (NASDAQ:DXR) Stock Price Up 13.5% – Here’s Why

Daxor Corporation (NASDAQ:DXR)’s share price rose 13.5% during mid-day trading on Tuesday . The company traded as high as $13.51 and last traded at $13.00. Approximately 21,337 shares were traded during mid-day trading, an increase of 249% from the average daily volume of 6,105 shares. The stock had previously closed at $11.45.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “hold (c-)” rating on shares of Daxor in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Daxor has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Daxor Stock Performance

The stock’s 50 day moving average price is $12.14 and its two-hundred day moving average price is $10.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Daxor stock. Osaic Holdings Inc. acquired a new position in shares of Daxor Corporation (NASDAQ:DXR) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned 0.18% of Daxor at the end of the most recent reporting period. 1.34% of the stock is owned by institutional investors and hedge funds.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.